Nitrous oxide-induced myeloneuropathy: a case series

J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):681-688. doi: 10.1136/jnnp-2023-331131. Epub 2023 May 30.

Abstract

Background: Nitrous oxide (N2O) is the second most common recreational drug used by 16- to 24-year-olds in the UK. Neurological symptoms can occur in some people that use N2O recreationally, but most information comes from small case series.

Methods: We describe 119 patients with N2O-myeloneuropathy seen at NHS teaching hospitals in three of the UK's largest cities: London, Birmingham and Manchester. This work summarises the clinical and investigative findings in the largest case series to date.

Results: Paraesthesia was the presenting complaint in 85% of cases, with the lower limbs more commonly affected than the upper limbs. Gait ataxia was common, and bladder and bowel disturbance were frequent additional symptoms. The mid-cervical region of the spinal cord (C3-C5) was most often affected on MRI T2-weighted imaging. The number of N2O canisters consumed per week correlated with methylmalonic acid levels in the blood as a measure of functional B12 deficiency (rho (ρ)=0.44, p=0.04).

Conclusions: Preventable neurological harm from N2O abuse is increasingly seen worldwide. Ease of access to canisters and larger cylinders of N2O has led to an apparent rise in cases of N2O-myeloneuropathy in several areas of the UK. Our results highlight the range of clinical manifestations in a large group of patients to improve awareness of risk, aid early recognition, and promote timely treatment.

Keywords: B12 deficiency; clinical neurology; myelopathy; neuropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Nitrous Oxide / adverse effects
  • Paresthesia
  • Spinal Cord Diseases* / chemically induced
  • Spinal Cord Diseases* / diagnostic imaging
  • Substance-Related Disorders*

Substances

  • Nitrous Oxide